CardioMech's transcatheter chordae tendineae repair system uses a catheter to attach an anchor on the mitral valve leaflet and then attaches it via a cord to the apex of the heart.
August 5, 2020 – Minneapolis-based CardioMech AS, a medical device company developing a transfemoral, transseptally delivered mitral valve repair technology, announced it has closed on its Series A financing led by a non-disclosed strategic investor together with healthcare specialist investor Hadean Ventures and Investinor. The $18.5 million in financing will fund its first-in-human feasibility trial.
CardioMech is developing a catheter-based mitral valve repair technology as an alternative to open-heart cardiac surgery to repair the chordae tendineae that tether the valve leaflets. The new technology enables placement of artificial chord(s) in the heart via a catheter to reduce or eliminate mitral regurgitation without opening the chest, stopping the heart, or going on heart-lung bypass.
"I am thrilled to partner with our strategic investor, Hadean and Investinor, leading global players in the development of medical device technologies," said Rick Nehm, President and CEO of CardioMech. "Together we will pursue and achieve our objective to significantly improve the standard of care for patients suffering from mitral regurgitation."
"We are very excited to join a key strategic investor to fund CardioMech to its feasibility study, not only because we see it as the most promising technology in the mitral market, but also because of its potential to have a significant and meaningful impact on so many patients suffering from mitral regurgitation around the world," said Ingrid Teigland Akay, M.D., MBA, Managing Partner of Hadean Ventures.
"CardioMech has the right technology, the right team, the right partners in the right market and Investinor is excited to invest in the development of this Norwegian-born technology," said Ann-Tove Kongsness, investment director, Investinor.
Mitral regurgitation, the backward flow of blood across the mitral valve, occurs when the mitral valve leaflets do not close properly and is the third most common cardiovascular disease. The market to treat this condition is widely expected to be significantly larger than the TAVR market, currently a $4 billion market.
For more information: www.cardiomech.com
March 31, 2025 
